Cypherpunk Technologies Inc.
CYPH Healthcare Biotechnology
In the quarter to June 2026, EPS grew 152.5% and free cash flow grew 15.5%, each against the same quarter a year earlier.
Follow CYPH
Cypherpunk Technologies Inc. (CYPH) EV/Sales
As of 16 October 2026, Cypherpunk Technologies Inc. (CYPH) trades at a EV/Sales of 311×. Over the past ten years it has ranged from −48.1× (September 2023) to 501× (September 2026); the current reading is higher than 99% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2021 | 109× | 100.40% |
| FY2020 | 54.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2021 | 109× | (13.62%) |
| Sep 2021 | 126× | 110.94% |
| Jun 2021 | 59.7× | (11.89%) |
| Mar 2021 | 67.8× | 24.83% |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. compare | 2.0× |
| AGEN Agenus Inc. compare | 2.1× |
| CCCC C4 Therapeutics, Inc. compare | 3.6× |
| ARCT Arcturus Therapeutics Holdings Inc. compare | 6.1× |
| OBIO Orchestra BioMed Holdings, Inc. compare | 8.5× |
| IRD Opus Genetics, Inc. compare | 31.5× |
| CYPH Cypherpunk Technologies Inc. | 311× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)